lonafarnib has been researched along with zoledronic acid in 7 studies
| Studies (lonafarnib) | Trials (lonafarnib) | Recent Studies (post-2010) (lonafarnib) | Studies (zoledronic acid) | Trials (zoledronic acid) | Recent Studies (post-2010) (zoledronic acid) |
|---|---|---|---|---|---|
| 224 | 34 | 90 | 4,108 | 620 | 2,610 |
| Protein | Taxonomy | lonafarnib (IC50) | zoledronic acid (IC50) |
|---|---|---|---|
| Carbonic anhydrase 12 | Homo sapiens (human) | 0.316 | |
| Geranylgeranyl pyrophosphate synthase | Homo sapiens (human) | 0.318 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 0.062 | |
| 72 kDa type IV collagenase | Homo sapiens (human) | 7 | |
| Farnesyl pyrophosphate synthase | Homo sapiens (human) | 0.2144 | |
| Farnesyl diphosphate synthase | Escherichia coli K-12 | 1.1 | |
| Farnesyl pyrophosphate synthase | Leishmania donovani | 0.11 | |
| Geranylgeranyl pyrophosphate synthase | Saccharomyces cerevisiae S288C | 0.424 | |
| Carbonic anhydrase 9 | Homo sapiens (human) | 5.323 | |
| Carbonic anhydrase 14 | Homo sapiens (human) | 0.092 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Baulch-Brown, C; Ma, D; Molloy, TJ; Spencer, A; Yeh, SL | 1 |
| Jiang, K | 1 |
| Brazier, J; Brown, WT; Campbell, SE; D'Agostino, RB; Gordon, LB; Kieran, MW; Kleinman, ME; Massaro, J | 1 |
| Hisama, FM; Martin, GM; Oshima, J | 1 |
| Cleveland, RH; D'Agostino, RB; Dowton, AA; Gerhard-Herman, M; Gordon, CM; Gordon, LB; Greer, MM; Huh, SY; Kieran, MW; Kleinman, ME; Liang, MG; Littlefield, K; Massaro, J; Miller, DT; Nazarian, A; Quinn, N; Shappell, H; Silvera, VM; Smoot, LB; Snyder, BD; Ullrich, NJ | 1 |
| Baltrusaitis, K; Braddock, DT; Cleveland, RH; D'Agostino, RB; Gordon, CM; Gordon, LB; Kieran, MW; Kleinman, ME; Li, X; Liang, MG; Massaro, J; Snyder, B; Walters, M | 1 |
| Cabral, WA; Collins, FS; Cubria, MB; DuBose, A; Erdos, MR; Kamalapathy, P; Karim, L; Masoudi, A; Nazarian, A; Oftadeh, R; Snyder, BD; Suarez, S | 1 |
1 trial(s) available for lonafarnib and zoledronic acid
| Article | Year |
|---|---|
Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome.
Topics: Bone and Bones; Carotid Arteries; Child, Preschool; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Infant; Male; Piperidines; Pravastatin; Progeria; Prospective Studies; Protein Prenylation; Pyridines; Zoledronic Acid | 2016 |
6 other study(ies) available for lonafarnib and zoledronic acid
| Article | Year |
|---|---|
Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphosphonates; Drug Screening Assays, Antitumor; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Imidazoles; Indoles; Mevalonic Acid; Multiple Myeloma; Piperidines; Pyridines; Structure-Activity Relationship; Zoledronic Acid | 2007 |
Drug development for progeria yields insights into normal aging.
Topics: Aging; Child; Clinical Trials as Topic; Diphosphonates; Drug Discovery; Humans; Imidazoles; Lamin Type A; Mutation; Piperidines; Pravastatin; Progeria; Pyridines; Time Factors; Zoledronic Acid | 2013 |
Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome.
Topics: Adolescent; Adult; Alkyl and Aryl Transferases; Atherosclerosis; Cause of Death; Child; Child, Preschool; Clinical Trials as Topic; Cohort Studies; Dimethylallyltranstransferase; Diphosphonates; Drug Therapy, Combination; Female; Genes, Dominant; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Kaplan-Meier Estimate; Lamin Type A; Male; Multicenter Studies as Topic; Nuclear Proteins; Piperidines; Pravastatin; Progeria; Proportional Hazards Models; Protein Precursors; Protein Prenylation; Pyridines; Treatment Outcome; Young Adult; Zoledronic Acid | 2014 |
An encouraging progress report on the treatment of progeria and its implications for atherogenesis.
Topics: Diphosphonates; Female; Humans; Imidazoles; Lamin Type A; Male; Nuclear Proteins; Piperidines; Pravastatin; Progeria; Protein Precursors; Protein Prenylation; Pyridines; Zoledronic Acid | 2014 |
Extraskeletal Calcifications in Hutchinson-Gilford Progeria Syndrome.
Topics: Calcinosis; Calcium; Child; Child, Preschool; Creatinine; Female; Fibroblast Growth Factor-23; Humans; In Vitro Techniques; Lamin Type A; Male; Parathyroid Hormone; Piperidines; Pravastatin; Progeria; Pyridines; Zoledronic Acid | 2019 |
Evaluation of musculoskeletal phenotype of the G608G progeria mouse model with lonafarnib, pravastatin, and zoledronic acid as treatment groups.
Topics: Aging; Animals; Bone and Bones; Bone Density Conservation Agents; Cartilage; Disease Models, Animal; Femur; Glycosaminoglycans; Joints; Lamin Type A; Mice; Mice, Transgenic; Mutation; Osteoarthritis; Phenotype; Piperidines; Pravastatin; Progeria; Protein Processing, Post-Translational; Pyridines; X-Ray Microtomography; Zoledronic Acid | 2020 |